ELVN241220C30000
- 1.29
- 0.000.00%
Enliven Therapeutics Newsroom
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Enliven Therapeutics Analyst Ratings
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36
Enliven Therapeutics Analyst Ratings
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37
Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
H.C. Wainwright Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $37
HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37
Enliven Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Ascendis Pharma (ASND)
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $39
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38